Ezra Funded $21M for AI-Powered Early Cancer Detection


Ezra is a NYC-based developer of screening equipment designed to make early cancer screening detection more accessible and affordable. The company’s equipment uses artificial intelligence to run MRI scans analyzed by expert radiologists in a single session and analyze.

Ezra was funded $21 million led by Healthier Capital and FirstMark Capital, with participation from Allianz Life Ventures, the Schwarzman family, former Chairman of England’s National Health Service (NHS) Lord David Prior, strategic angel investors of Gaingels, Republic, Mana Ventures, and existing investors.

The funds will be instrumental in advancing their cutting-edge technology, which aims to revolutionize the landscape of cancer diagnosis.

Ezra’s innovative approach involves leveraging AI algorithms to analyze medical imaging data, enabling the early detection of various types of cancer. With this new injection of capital, the company is poised to accelerate its research and development efforts, enhance its AI capabilities, and broaden the scope of its early detection platform.

The company’s mission is to make cancer screening more accessible, efficient, and accurate, leading to earlier intervention and better chances of successful treatment.

Ezra’s CEO, Emi Gal, expressed gratitude for the support and emphasized the transformative potential of their AI-powered solution. They are thrilled to have the backing of our investors as they continue to push the boundaries of what is possible in early cancer detection. This funding will enable them to expand their research, strengthen their partnerships, and ultimately bring their technology to more people around the globe.

The company’s AI algorithms are designed to analyze various medical imaging modalities, including magnetic resonance imaging (MRI) scans, to identify potential signs of cancer at an early stage. By focusing on early detection, Ezra aims to improve survival rates and reduce late-stage cancer diagnoses’ economic and emotional impact.

Ezra’s success in securing new funding underscores the growing interest and confidence in the potential of AI to transform healthcare. As the company continues to advance its technology, the impact on the field of oncology could be profound, offering new hope for individuals at risk of developing cancer and providing healthcare professionals with powerful tools for more effective diagnosis and treatment planning.

With this latest funding boost, Ezra is well-positioned to cement its role as a leader in the intersection of AI and healthcare further, bringing us one step closer to a future where early cancer detection is not only possible but also more accessible than ever before.

By: K. Tagura

Author statement:

Who we are: Funded.com is a platform that is A+ BBB accredited over 10+ years. Access our network of Angel Investors, Venture Capital or Lenders. Let us professionally write your Business Plan.